General Information of Drug (ID: DMWY0V1)

Drug Name
LIPO-5 Drug Info
Synonyms HIV vaccine (lipoprotein), ANRS/Aventis Pasteur
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMWY0V1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
F4co vaccine DM6UQNW Human immunodeficiency virus infection 1C62 Phase 2 [3]
Ad35-GRIN DM4L28K Human immunodeficiency virus infection 1C62 Phase 1/2 [4]
Ad35-GRIN/ENV DMG82ZA Human immunodeficiency virus infection 1C62 Phase 1 [4]
GSK-732461 DMJ0ZB6 Human immunodeficiency virus infection 1C62 Discontinued in Phase 2 [5]
MYRISTIC ACID DMYX0BL Discovery agent N.A. Investigative [6]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bevirimat DML2D8Q Human immunodeficiency virus infection 1C62 Phase 2 [7]
Ad35-GRIN DM4L28K Human immunodeficiency virus infection 1C62 Phase 1/2 [4]
Ad35-GRIN/ENV DMG82ZA Human immunodeficiency virus infection 1C62 Phase 1 [4]
TBC-M4 DM9CDPO Human immunodeficiency virus infection 1C62 Phase 1 [8]
RVSVIN HIV-1 gag vaccine DMYRPC8 Human immunodeficiency virus infection 1C62 Phase 1 [9]
GSK-732461 DMJ0ZB6 Human immunodeficiency virus infection 1C62 Discontinued in Phase 2 [5]
PA-1050040 DMF4KPM Human immunodeficiency virus infection 1C62 Discontinued in Phase 1 [10]
Gem 92 DM4ZDVY Human immunodeficiency virus-1 infection 1C62 Discontinued in Phase 1 [11]
MPC-9055 DMCMNKV Human immunodeficiency virus infection 1C62 Discontinued in Phase 1 [12]
MPI-461359 DMAVD4Q Human immunodeficiency virus infection 1C62 Terminated [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus GAG protein (HIV gag) TTFGZB6 GAG_HV1H2 Not Available [2]
Human immunodeficiency virus Negative factor (HIV nef) TT4NXYM NEF_HV1A2 Not Available [2]

References

1 ClinicalTrials.gov (NCT01492985) Lipopeptide Immunisation With GTU-multiHIV Trial. U.S. National Institutes of Health.
2 HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
3 EP patent application no. 2621528, Vaccine.
4 A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
5 Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
6 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
7 Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65.
8 A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
9 Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81.
10 US patent application no. 2015,0105,350, Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections.
11 Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther. 1999 Aug;1(4):521-3.
12 New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation . Antimicrob Agents Chemother. 2009 December; 53(12): 5080-5087.
13 Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012 Aug 6;9:63.